Comparative evaluation of selected sex hormones in premenopausal and postmenopausal women with breast cancer

Paper Details

Research Paper 01/12/2019
Views (359) Download (18)
current_issue_feature_image
publication_file

Comparative evaluation of selected sex hormones in premenopausal and postmenopausal women with breast cancer

Nadeem Ahmad, Saeeda Kalsoom, Zahed Mahmood, Muhammad Riaz, Imtiaz Mahmood Tahir, Akhtar Rasul, Haroon Ur Rashid, Syed Muhammad Ali Shah, Naveed Munir, Muhammad Akram
Int. J. Biosci.15( 6), 16-25, December 2019.
Certificate: IJB 2019 [Generate Certificate]

Abstract

Breast cancer is the second most common cancer among women with respect to gender and manifold evidence support a vital role of hormones in the etiology of this cancer as sex steroids stimulate the development and proliferation of breast cells. The present study was planned to investigate the relationship of selective female sex hormones including estradiol, progesterone and testosterone in premenopausal and postmenopausal women with breast cancer from local areas of Punjab, Pakistan. Total 150 selected subjects divided into three main groups; control group (n=40) (premenopausal and postmenopausal) (n=20 each) not having breast disease or hormone related tumors or any other disease, 59 premenopausal patients and 51 postmenopausal patients having breast cancer. Pre and postmenopausal patients were divided further into three patient groups; a) newly diagnosed b) under treatment and c) treated. After evaluation, the blood hormone levels by Electro Chemi Luminescence immunoassay, one-way analysis of variance (ANOVA) and least significant difference (LSD) tests were used to evaluate results statistically. Results showed that non-significant relationship found between estradiol (p = 0.364), progesterone (p = 0.603), testosterone (p = 0.458) in premenopausal women and breast cancer. Significant relationship was found between estradiol (p < 0.05) and testosterone (p < 0.05) in postmenopausal females with breast cancer while progesterone showed non-significant association (p > 0.05) with breast cancer. The study concluded that serum estradiol and testosterone levels in postmenopausal women could be associated with breast cancer.

VIEWS 22

Bernstein L,  Ross RK. 1993. Endogenous hormones and breast cancer risk. Epidemiologic Reviews 15, 48-65.

Blackburn GF, Shah HP, Kenten JH, Leland J, Kamin RA, Link J, Peterman J, Powell MJ, Shah A, Talley DB. 1991. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clinical Chemistry 37, 1534-1539.

Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, Knight JA, Olivotto IA, Quan ML, Friedenreich CM. 2016. Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer causes and control, 27, 459-472.

Brown SB, Hankinson SE. 2015. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 99, 8-10.

Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA. 2010. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Research, 12, R98.

Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, Ahern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A. 2010. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor–positive breast cancer in postmenopausal women. Journal of Clinical Oncology 28, 1161.

Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. 2006. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of National Cancer Institute 98, 1406-15.

Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, Gierach GL. 2013. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Research, 15, R34.

Hankinson SE, Willet WC, Coldits GA. 2004. Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Research 6, 213–18.

Hankinson SE, Eliassen AH. 2007. Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. The Journal of steroid biochemistry and molecular biology, 106, 24-30.

Hankinson SE, Manson J, Spiegelman D, Willett WC, Longcope C, Speizer FE. 1995. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiology and Prevention Biomarkers, 4, 649-654.

Ho CC, Rohaizak M, Zulkifli SZ, Siti-aishah MA, Nor-Aini U, Sharifah-Noor-Akmal SH. 2009. Serum sex hormone levels in pre- and postmenopausal breast cancer patients. Singapore Medical Journal, 50, 513-18.

John EPA, Davis A, Koo J. 2005. Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiology Biomarkers Prevevtion 14, 2905-13.

Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno DMH. 2005. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of National Cancer Institute, 97, 755-65.

Kenten J, Gudibande S, Link J, Willey J, Curfman B, Major E, Massey R. 1992. Improved electrochemiluminescent label for DNA probe assays: rapid quantitative assays of HIV-1 polymerase chain reaction products. Clinical Chemistry 38, 873-879.

Kenten JH, Casadei J, Link J, Lupold S, Willey J, Powell M, Rees A, Massey R. 1991. Rapid electrochemiluminescence assays of polymerase chain reaction products. Clinical Chemistry 37, 1626-1632.

Key T, Appleby P, Barnes I, Reeves G. 2002. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of National Cancer Institute 94, 606-16.

Key TJ, Appleby PN, Reeves GK, Travis RC, Brinton LA, Helzlsouer KJ, Dorgan JF, Gapstur SM, Gaudet MM, Kaaks R, Riboli E, Rinaldi S, Manjer J, Hallmans G, Giles GG, Marchand L, Kolonel LN, Henderson BE, Tworoger SS, Hankinson SE, Zeleniuch-Jacquotte A, Koenig K, Krogh V, Sieri S, Muti P, Ziegler RG, Schairer C, Fuhrman BJ, Barrett-Connor E, Laughlin GA, Grant EJ, Cologne J, Ohishi W, Hida A, Cauley JA, Fourkala EO, Menon U, Rohan TE, Strickler HD, Mj G. 2015. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: reanalysis of eighteen prospective studies. Steroids 99, 49-55.

Key TJ, Pike MC. 1988. The role of estrogens and progesterone in the epidemiology and prevention of breast cancer. European Journal of Cancer and Clinical Oncology 24, 29-43.

Labrie F, Belanger A, Lin S, Simard J, Pelletier G, Labrie C. 2005. Is dehydroepiandrosterone a hormone? Journal of Endocrinology 187, 169-196.

Lange CA, Yee D. 2008. Progesterone and breast cancer. Women’s Health 4, 151-162.

Leland JK, Powell MJ. 1990. Electrogenerated chemiluminescence: an oxidative‐reduction type ECL reaction sequence using tripropyl amine. Journal of the Electrochemical Society 137, 3127-3131.

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. 2004. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute 96, 1856-65.

Obeng YS, Bard AJ. 1991. Electrogenerated chemiluminescence. 53. Electrochemistry and emission from adsorbed monolayers of a tris (bipyridyl) ruthenium (II)-based surfactant on gold and tin oxide electrodes. Langmuir, 7, 195-201.

Osborne MP, Bradlow HL, Wong GY, Telang NT. 1993. Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. Journal of the National Cancer Institute 85, 1917-20.

Pal B, Bouras T, Shi W, Vaillant F, Sheridan JM, Fu N, Breslin K, Jiang K, Ritchie ME, Young M. 2013. Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell reports 3, 411-426.

Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer Journal of Clinician 55, 74-108.

Riaz M, Mahmood Z, Shahid M, Saeed MUQ, Tahir IM, Shah SA, Munir N, El-Ghorab A. 2016. Impact of reactive oxygen species on antioxidant capacity of male reproductive system. International journal of immunopathology and pharmacology 29, 421-425.

Russo J, Russo IH. 2006. The role of estrogen in the initiation of breast cancer. Journal Steroid Biochemistry and Molecular Biology, 102, 89-96.

Shufelt CL, Braunstein GD, Shufelt CL. 2008. Testosterone and the breast. Menopause International, 14, 117-22.

Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ, Mendelson CR. 1993. Tissue-specific promoters regulate aromatase cytochrome P450 expression. The Journal of steroid biochemistry and molecular biology 44, 321-330.

Somboonporn W, Davis SR. 2004. Postmenopausal testosterone therapy and breast cancer risk. Maturitas 49, 267-275.

Telang NT, Katdare M, Bradlow HL, Osborne MP. 1997. Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Environmental Health Perspect 105, 559–564.

Thomas DB. 1984. Do hormones cause breast cancer? Cancer 53, 595-604.

Thomas HV, Reeves GK, Key TJ. 1997. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control, 8, 922-28.

Ursin G, Wilson M, Henderson BE, Kolonel LN, Monroe K, Lee HP, Seow A, Mimi CY, Stanczyk FZ, Gentzschein E. 2001. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer  research 61, 3326-3329.

VanDenBrandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR. 2000. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. American Journal of Epidemiology 152, 514-27.

Xu XH, Bard AJ. 1994. Electrogenerated chemiluminescence. 55. Emission from adsorbed Ru (bpy) 32+ on graphite, platinum, and gold. Langmuir, 10, 2409-2414.

Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. 2013. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast cancer research and treatment, 137, 883-892.

Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D,  Felson DT. 1997. Bone mass and the risk of breast cancer among postmenopausal women. New England Journal of Medicine 336, 611-7.